Cargando…

Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B

Adefovir (ADV) sequential monotherapy was included in the 2005 Asia-Pacific guidelines for the management of patients with lamivudine (LAM) resistance. However, following the development of ADV resistance, the proportion of resistant variants during combined rescue therapy with ADV and entecavir (ET...

Descripción completa

Detalles Bibliográficos
Autores principales:	WANG, YANG, LIU, SHUANG, CHEN, YU, ZHENG, SUJUN, ZHOU, LI, LU, FENGMIN, DUAN, ZHONGPING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888018/ https://www.ncbi.nlm.nih.gov/pubmed/27313669 http://dx.doi.org/10.3892/etm.2016.3230

Ejemplares similares

Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice
por: Liu, Yan, et al.
Publicado: (2019)

rtM204Q May Serve as a Novel Lamivudine-Resistance-Associated Mutation of Hepatitis B Virus
por: Liu, Yan, et al.
Publicado: (2014)

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy
por: Wang, Yang, et al.
Publicado: (2015)

Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
por: Choe, Won Hyeok, et al.
Publicado: (2019)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019)

Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi
por: Lai, Ming-Wei, et al.
Publicado: (2020)

Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
por: Kim, Jihyun, et al.
Publicado: (2015)

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
por: Woo, Hyun Young, et al.
Publicado: (2014)

Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy
por: Wang, Changtai, et al.
Publicado: (2019)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice
por: Xu, Xian-Hua, et al.
Publicado: (2013)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation
por: Lee, Jae Geun, et al.
Publicado: (2015)

Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
por: Liu, Fen, et al.
Publicado: (2014)

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
por: Wu, Xiaoning, et al.
Publicado: (2019)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
por: Cassino, Lucila, et al.
Publicado: (2011)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
por: Chae, Hee Bok, et al.
Publicado: (2012)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
por: Li, Ping, et al.
Publicado: (2017)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Excitation of the high-spin isomers $^{180m}$Hf, $^{190m}$Os and $^{204m}$Pb in ($\gamma$,$\gamma$') reactions
por: Balabanov, N P, et al.
Publicado: (1993)

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
por: Wang, Zhao, et al.
Publicado: (2011)

M10.6.8: Integration of downconverters and upconverters in RTM (ATCA)
por: Czuba, K, et al.
Publicado: (2011)

Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients
por: Pereira-Gómez, Marianoel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7dd175rromc39b2g8cq4gt34up